


# How Beovu® (brolucizumab) works in wet AMD

Wet age-related macular degeneration (wet AMD) is an eye disease that damages a portion of the retina called the macula.<sup>1</sup> A healthy macula is required for good vision. The disease is a leading cause of vision loss and blindness worldwide, affecting 20 million people across the world.<sup>2-4</sup>

## What causes wet AMD?



## Finding the fluid

Eye doctors use a type of imaging called OCT to identify fluid in the retina.<sup>6</sup> A healthy retina is dry, so signs of fluid in an OCT image indicate disease.





Image representational of baseline OCT scan from patient in HAWK & HARRIER.

## How Beovu works



Beovu binds to VEGF-A, slowing abnormal blood vessel growth and leaking fluid.<sup>7,8</sup> Advanced engineering makes Beovu a potent inhibitor of VEGF-A.<sup>8</sup>

## Signs Beovu is working

Less fluid in an OCT image suggests treatment is working.<sup>9</sup> Plus, vision can be maintained or even improved.<sup>8</sup>




Image representational of baseline OCT scan from patient in HAWK & HARRIER.




Image representational of an OCT scan from Beovu patient at week 48 in HAWK and HARRIER. Individual results may vary.

1. National Eye Institute. Facts About Age-Related Macular Degeneration. Available at <https://nei.nih.gov/eyedata/amd> (link is external). Accessed August 2019. 2. Schmidt-Erfurth U, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). *Br J Ophthalmol*. 2014;98:1144-1167. 3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and met analysis. *Lancet Glob Health*. 2014;2:106-16. 4. Singer M. Advances in the management of macular degeneration. *F1000Prime Rep*. 2014;6:29. 5. Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. *Indian J Ophthalmol*. 2007;55(6):413-415. 6. Kang SW, et al. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. *Am J Ophthalmol* 2004;137(2):313-322. 7. Beovu [prescribing information] East Hanover, NJ. Novartis: 2019. 8. Dugel P, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration [published online ahead of print]. *Ophthalmology*. 2019. 9. Rosenfeld P. Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2016;57(9): OCT14-OCT26